Correction to: HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

Betül Altunay¹, Agnieszka Morgenroth¹, Mohsen Beheshti^{1

2

3}, Andreas Vogg¹, Nicholas C L Wong⁴, Hong Hoi Ting⁴, Hans-Jürgen Biersack⁵, Elmar Stickeler^{2

6}, Felix M Mottaghy^{7

8

9}

Affiliations

¹ Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.
² Center of Integrated Oncology (CIO), Cologne and Düsseldorf, Universities of Aachen, Kerpener Str. 62, 50937, Bonn, Cologne, Germany.
³ Division of Molecular PET-Imaging and Theranostics, Paracelsus Medical University, 5020, Salzburg, Austria.
⁴ Nanomab Technology Limited, Shanghai, People's Republic of China.
⁵ Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
⁶ Department of Gynecology and Obstetrics, RWTH Aachen, Aachen, Germany.
⁷ Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany. fmottaghy@ukaachen.de.
⁸ Center of Integrated Oncology (CIO), Cologne and Düsseldorf, Universities of Aachen, Kerpener Str. 62, 50937, Bonn, Cologne, Germany. fmottaghy@ukaachen.de.
⁹ Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), 6202, Maastricht, The Netherlands. fmottaghy@ukaachen.de.

Published Erratum

Betül Altunay et al. Eur J Nucl Med Mol Imaging. 2024 Sep.

. 2024 Sep;51(11):3485.

doi: 10.1007/s00259-024-06792-w.

¹ Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.
² Center of Integrated Oncology (CIO), Cologne and Düsseldorf, Universities of Aachen, Kerpener Str. 62, 50937, Bonn, Cologne, Germany.
³ Division of Molecular PET-Imaging and Theranostics, Paracelsus Medical University, 5020, Salzburg, Austria.
⁴ Nanomab Technology Limited, Shanghai, People's Republic of China.
⁵ Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
⁶ Department of Gynecology and Obstetrics, RWTH Aachen, Aachen, Germany.
⁷ Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany. fmottaghy@ukaachen.de.
⁸ Center of Integrated Oncology (CIO), Cologne and Düsseldorf, Universities of Aachen, Kerpener Str. 62, 50937, Bonn, Cologne, Germany. fmottaghy@ukaachen.de.
⁹ Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), 6202, Maastricht, The Netherlands. fmottaghy@ukaachen.de.

No abstract available

Erratum for

HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.
Altunay B, Morgenroth A, Beheshti M, Vogg A, Wong NCL, Ting HH, Biersack HJ, Stickeler E, Mottaghy FM. Altunay B, et al. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1371-1389. doi: 10.1007/s00259-020-05094-1. Epub 2020 Nov 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 33179151 Free PMC article. Review.